Personalis, Inc. $PSNL Stock Purchased by Aberdeen Group plc

Key Points

• Aberdeen Group increased its Personalis stake by 39.1% in the third quarter, adding 1.46 million shares to reach 5.21 million shares, or about 4.98% of the company.
• Hedge funds and other institutional investors own 61.91% of Personalis; several other firms also initiated or expanded positions recently.
• Personalis beat revenue expectations for the quarter with $25.6 million, but its loss per share of $0.32 was wider than analysts expected. Analysts’ consensus rating was Hold, with an average price target of $15.29.

Aberdeen Group plc lifted its holdings in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 39.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 5,211,939 shares of the company's stock after purchasing an additional 1,464,649 shares during the period. Aberdeen Group plc owned about 4.98% of Personalis worth $84,850,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in shares of Personalis in the 2nd quarter valued at about $69,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Personalis in the 3rd quarter worth approximately $89,000. ADAR1 Capital Management LLC acquired a new stake in Personalis in the first quarter valued at approximately $159,000. Fortitude Family Office LLC acquired a new stake in Personalis in the third quarter valued at approximately $164,000. Finally, Penobscot Investment Management Company Inc. acquired a new stake in Personalis in the third quarter valued at approximately $182,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Stock Performance

Shares of Personalis stock traded down $0.15 on Friday, hitting $15.71. The company's stock had a trading volume of 2,803,799 shares, compared to its average volume of 2,199,010. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -13.43 and a beta of 2.40. The firm has a fifty day moving average price of $16.08 and a 200-day moving average price of $11.61. Personalis, Inc. has a 1 year low of $4.95 and a 1 year high of $18.89.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06). Personalis had a negative net margin of 147.74% and a negative return on equity of 49.53%. The business had revenue of $25.60 million for the quarter, compared to analysts' expectations of $21.54 million.

Insider Activity at Personalis

In other Personalis news, SVP Stephen Moore sold 2,068 shares of the stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $33,542.96. Following the transaction, the senior vice president directly owned 90,257 shares of the company's stock, valued at $1,463,968.54. This trade represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Richard Chen sold 3,998 shares of Personalis stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $64,847.56. Following the completion of the sale, the chief marketing officer owned 169,882 shares in the company, valued at approximately $2,755,486.04. This trade represents a 2.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 16,456 shares of company stock valued at $266,916. Insiders own 4.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Craig Hallum lowered shares of Personalis from a "buy" rating to a "hold" rating and set a $16.25 price target on the stock. in a research note on Monday, August 24th. Zacks Research raised Personalis from a "strong sell" rating to a "hold" rating in a research report on Monday, September 7th. BTIG Research lowered Personalis from a "buy" rating to a "neutral" rating in a research note on Tuesday, October 6th. Needham & Company LLC cut Personalis from a "buy" rating to a "hold" rating in a report on Monday, July 20th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Personalis in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $15.29.

Personalis Profile

Personalis is a cancer genomics company that develops sequencing and data-analysis tools for cancer research and personalized cancer care. Its services support pharmaceutical and biotechnology companies, academic researchers, and clinicians studying cancer and evaluating treatments. The company's offerings include NeXT Personal, a blood-based test designed to detect molecular residual disease and monitor cancer recurrence using circulating tumor DNA. Personalis also provides tumor profiling and immunogenomics services that analyze cancer-related genetic changes and features of the tumor immune environment.

Want to see what other hedge funds are holding PSNL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Personalis, Inc. (NASDAQ:PSNL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.